California State Teachers Retirement System Acquires 1,064 Shares of Illumina, Inc. (NASDAQ:ILMN)

California State Teachers Retirement System increased its holdings in shares of Illumina, Inc. (NASDAQ:ILMN) by 0.4% in the first quarter, according to its most recent disclosure with the SEC. The firm owned 253,629 shares of the life sciences company’s stock after purchasing an additional 1,064 shares during the period. California State Teachers Retirement System owned 0.16% of Illumina worth $34,828,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors have also bought and sold shares of the business. Bouvel Investment Partners LLC grew its holdings in Illumina by 1.3% during the first quarter. Bouvel Investment Partners LLC now owns 6,547 shares of the life sciences company’s stock worth $899,000 after purchasing an additional 84 shares during the period. STF Management LP boosted its holdings in shares of Illumina by 3.5% during the fourth quarter. STF Management LP now owns 2,644 shares of the life sciences company’s stock worth $368,000 after acquiring an additional 90 shares during the period. Global Retirement Partners LLC boosted its holdings in shares of Illumina by 12.3% during the first quarter. Global Retirement Partners LLC now owns 856 shares of the life sciences company’s stock worth $118,000 after acquiring an additional 94 shares during the period. Gulf International Bank UK Ltd boosted its holdings in shares of Illumina by 0.7% during the first quarter. Gulf International Bank UK Ltd now owns 13,562 shares of the life sciences company’s stock worth $1,862,000 after acquiring an additional 98 shares during the period. Finally, Clear Creek Financial Management LLC boosted its holdings in shares of Illumina by 6.3% during the fourth quarter. Clear Creek Financial Management LLC now owns 1,695 shares of the life sciences company’s stock worth $236,000 after acquiring an additional 100 shares during the period. Institutional investors own 89.42% of the company’s stock.

Analysts Set New Price Targets

A number of equities research analysts have recently issued reports on ILMN shares. Evercore ISI reduced their price objective on Illumina from $195.00 to $175.00 and set an “outperform” rating for the company in a report on Tuesday, June 11th. Barclays boosted their price objective on Illumina from $85.00 to $100.00 and gave the stock an “underweight” rating in a report on Wednesday, April 10th. Royal Bank of Canada cut their price target on Illumina from $249.00 to $242.00 and set an “outperform” rating for the company in a research note on Monday, July 1st. Jefferies Financial Group began coverage on Illumina in a research note on Monday, June 3rd. They issued a “hold” rating and a $115.00 price target for the company. Finally, Robert W. Baird boosted their price target on Illumina from $125.00 to $128.00 and gave the company a “neutral” rating in a research note on Friday, May 3rd. Two equities research analysts have rated the stock with a sell rating, ten have given a hold rating and ten have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, Illumina presently has a consensus rating of “Hold” and an average price target of $158.57.

Illumina Price Performance

Shares of ILMN traded up $0.10 during trading hours on Wednesday, reaching $122.60. The stock had a trading volume of 1,439,600 shares, compared to its average volume of 2,114,598. Illumina, Inc. has a 12 month low of $89.00 and a 12 month high of $195.64. The company has a quick ratio of 1.36, a current ratio of 1.75 and a debt-to-equity ratio of 0.26. The company’s 50-day moving average is $110.43 and its two-hundred day moving average is $123.83.

Illumina (NASDAQ:ILMN) last announced its quarterly earnings results on Thursday, May 2nd. The life sciences company reported $0.09 EPS for the quarter, beating analysts’ consensus estimates of $0.04 by $0.05. Illumina had a positive return on equity of 2.31% and a negative net margin of 28.71%. The company had revenue of $1.08 billion during the quarter, compared to analysts’ expectations of $1.05 billion. During the same period in the prior year, the company earned $0.08 EPS. Illumina’s revenue was down 1.0% compared to the same quarter last year. As a group, analysts forecast that Illumina, Inc. will post 1.38 EPS for the current fiscal year.

Illumina Company Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.